Calidi Biotherapeutics (CLDI) Payables (2021 - 2025)
Calidi Biotherapeutics' quarterly Payables came in at $600000.0 in Q4 2025, down 87.43% year-on-year from $4.8 million in Q4 2024, and up 48.15% quarter-over-quarter from $405000.0 in Q3 2025.
Calidi Biotherapeutics has reported Payables for 5 years, with the latest figure at $600000.0 in Q4 2025.
- For the quarter ending Q4 2025, Payables fell 87.43% year-over-year to $600000.0; the trailing twelve-month figure through Dec 2025 stood at $600000.0 (down 87.43% YoY), and the FY2025 full-year result was $600000.0, down 87.43% from the prior year.
- Payables for Q4 2025 stood at $600000.0, up from $405000.0 in the prior quarter.
- The five-year high for Payables was $10.1 million in Q3 2024, with the low at $27810.0 in Q2 2022.
- Average Payables over 5 years is $3.2 million, with a median of $1.6 million recorded in 2023.
- Year-over-year, Payables jumped 7010.12% in 2023 and slumped 95.99% in 2025.
- Tracing CLDI's Payables over 5 years: stood at $63839.0 in 2021, then soared by 5576.78% to $3.6 million in 2022, then retreated by 6.71% to $3.4 million in 2023, then surged by 41.14% to $4.8 million in 2024, then sank by 87.43% to $600000.0 in 2025.
- The last three Payables figures came in at $600000.0 (Q4 2025), $405000.0 (Q3 2025), and $812000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 1.03 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 600,000.00 |
| Sep 30, 2025 | 405,000.00 |
| Jun 30, 2025 | 812,000.00 |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 4.77 Mn |
| Sep 30, 2024 | 10.10 Mn |
| Jun 30, 2024 | 9.90 Mn |
| Mar 31, 2024 | 7.52 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Sep 30, 2023 | 8.40 Mn |
| Jun 30, 2023 | 1.98 Mn |
| Mar 31, 2023 | 1.61 Mn |
| Dec 31, 2022 | 3.62 Mn |
| Sep 30, 2022 | 563,082.00 |
| Jun 30, 2022 | 27,810.00 |
| Mar 31, 2022 | 41,518.00 |
| Dec 31, 2021 | 63,839.00 |